The role of radionuclide therapy in medullary thyroid cancer.
D019797:3-Iodobenzylguanidine / Q000627:therapeutic use; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002272:Carcinoembryonic Antigen / Q000276:immunology; D018276:Carcinoma, Medullary / Q000000981:diagnostic imaging* / Q000628:therapy*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004195:Disease Models, Animal; D006801:Humans; D015282:Octreotide / Q000627:therapeutic use; D010456:Peptides, Cyclic / Q000627:therapeutic use; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging* / Q000628:therapy*
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D002272:Carcinoembryonic Antigen; D010456:Peptides, Cyclic; D019275:Radiopharmaceuticals; C060347:lanreotide; D019797:3-Iodobenzylguanidine; D013004:Somatostatin; D015282:Octreotide